Sunesis Pharmaceuticals Inc (SNSS.OQ)
SNSS.OQ on NASDAQ Stock Exchange Capital Market
5.13USD
1 Aug 2013
5.13USD
1 Aug 2013
Price Change (% chg)
$0.05 (+0.98%)
$0.05 (+0.98%)
Prev Close
$5.08
$5.08
Open
$5.07
$5.07
Day's High
$5.14
$5.14
Day's Low
$4.98
$4.98
Volume
143,950
143,950
Avg. Vol
99,851
99,851
52-wk High
$6.84
$6.84
52-wk Low
$2.30
$2.30
About
Sunesis Pharmaceuticals, Inc. (Sunesis) is a biopharmaceutical company focused on the development and commercialization of oncology therapeutics for the treatment of solid and hematologic cancers. The Company is focuses primarily on the development of vosaroxin for the treatment of acute myeloid leukemia (AML). Vosaroxin is a... (more)
Overall
| Beta: | 2.14 |
| Market Cap (Mil.): | $262.17 |
| Shares Outstanding (Mil.): | 51.61 |
| Dividend: | -- |
| Yield (%): | -- |
Financials
| SNSS.OQ | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | -- | 47.13 | 37.76 |
| EPS (TTM): | -0.83 | -- | -- |
| ROI: | -264.23 | -2.58 | 18.76 |
| ROE: | -6,285.15 | -2.66 | 19.59 |
Competitors
| Price | Change | |
|---|---|---|
| Eisai Co., Ltd (4523.T) | ¥4,295 | +130.00 |
| Pfizer Inc. (PFE.N) | $29.11 | -0.12 |
| Johnson & Johnson (JNJ.N) | $93.77 | +0.27 |
| Novartis AG (NOVN.VX) | CHF66.60 | +0.35 |
| Merck & Co., Inc. (MRK.N) | $48.58 | +0.41 |
| Celgene Corporation (CELG.OQ) | $148.79 | +1.93 |
Earnings vs.
Estimates
Analyst Research Reports
| Report Title | Price |
|---|---|
|
Provider: Thomson Reuters Stock Report
|
$25.00
|
|
Provider: ValuEngine, Inc.
|
$25.00
|
|
Provider: Wright Reports
|
$472.00
|
|
Provider: Zacks Investment Research Inc.
|
$12.00
|
|
Provider: Zacks Investment Research Inc.
|
$12.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

